← All organizations
Highest phase reached
Phase 4
First clinical trial
Apr 1, 2001First marketed drug
Oct 20, 1997First NDA
Oct 20, 1997Last known activity
Oct 27, 2025
Timeline
1990s
- Jun 1, 1994
Bavarian Nordic— Founded
- Oct 20, 1997
inactivated rabies vaccine— NDA Organization
- Oct 20, 1997
inactivated rabies vaccine— NDA Secondary Org
Drugs by trial phase (39 distinct, 52 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (10 own, 0 via acquisition)
Phase 2 (20 own, 0 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Adenocarcinoma
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Communicable Diseases
- Dermatitis
- Dermatitis, Atopic
- Eczema
- Encephalitis
- Encephalomyelitis, Equine
- Hemorrhagic Fever, Ebola
- Hemorrhagic Fevers, Viral
- HIV Infections
- Infections
- Lung Neoplasms
- Measles
- Mpox, Monkeypox
- Neoplasm Metastasis
- Papillomavirus Infections
- Prostatic Neoplasms
- Respiratory Syncytial Virus Infections
- Rhinitis, Allergic, Seasonal
- Smallpox
- Urinary Bladder Neoplasms
- Vaccinia
- Virus Diseases
Marketed drugs (2)
Recent trials (50)
- NCT07199569Lead sponsorPhase 2Oct 27, 2025
- NCT06844500CollaboratorPhase 3Jun 23, 2025
- NCT07003984Lead sponsorPhase 3Jun 5, 2025
- NCT07003984OfficialPhase 3Jun 5, 2025
- NCT06844487CollaboratorPhase 3May 29, 2025
- NCT06899802Lead sponsorPhase 2Mar 10, 2025
- NCT06549530Lead sponsorPhase 2Oct 16, 2024
- NCT06007183Lead sponsorPhase 3Aug 30, 2023
- NCT06007183Study directorPhase 3Aug 30, 2023
- NCT05329220Lead sponsorPhase 3Aug 31, 2022
- NCT05329220Study directorPhase 3Aug 31, 2022
- NCT05238025Lead sponsorPhase 3Apr 19, 2022
- NCT05238025Study directorPhase 3Apr 19, 2022
- NCT05077267Lead sponsorPhase 2Aug 19, 2021
- NCT04752644Lead sponsorPhase 2Feb 22, 2021
Details
- Founded
- Kvistgaard, DK Jun 1, 1994
- First NDA
- Oct 20, 1997
- Last known activity
- Oct 27, 2025